



# Collaborating for the Future

**Sarah White**

**Natasha Owen**

**West of England Academic Health Science Network**

UKBAY09160139 Date of Preparation September 2016

# Let's Talk DWAC



## Phase 1 – The Pilot

Aim: To Optimise  
Anticoagulation for AF  
patients

Evaluation of results

# Developing the Project

- Clear evidence base – NICE CG180
- Engaged early with industry partners

- Boehringer Ingelheim
- Pfizer
- Bayer
- Daiichi Sankyo



# Start of the Collaboration



- Medical and Educational Grants and Services
  - BI
  - Bayer
- Supported various outputs; meetings, resources, training events
- DWAC is starting to take shape...

# DWAC takes off!


Phase 1 is a success, let's scale up!

- CCG engaged
- Development of resources
- Plan training
- Engage pharmacists
- Understand data requirements
- Communications strategy
- Relationship management

...



**We're going to need a bigger team...**



# New Year 2015



- Joint Working Agreement agreed for Phase 1
- Seconded team members
- To be based in our office
- Work alongside the QI team
- QI capacity increased



# In the beginning

- Emergent team processes
- Culture clash
- Steep learning curve



- Quality Improvement Support Team
- New team member



# How did it work out?



- Seconded for nearly two years
- Fully embedded team members
- Capacity to roll DWAC out at scale realised
- QI learning in situ
- 52 GP practices in Glos have received face to face support
- Partnership between AHSN and Bayer strengthened
- Skills shared
- Worked closely with other partners

Hello, We're

**AWESOME**

How can we help you?

# What did we gain from Collaboration?



People who were invested in the project  
Different 'voices'  
A flexible, mobile team  
Capacity to support GP practices  
QI learning and experience  
Lessons learnt first hand  
Success in Phase 2  
Team work  
Support  
Access to expertise  
Nominated for PF Award



# What about Bayer...?



Catalyst for partnership working approach and support credibility as a trusted partner

Increase in the focus from medical and legal departments to support the Bayer approach

Other AHSNs and CCGs wanting to work with Bayer on iterations of DWAC

Other departments within Bayer looking to do more JW with hospital trusts/networks/CCGs in the therapy areas of ophthalmology and cancer

A greater understanding of the issues faced by the NHS and how we can help

The building of trust and the increase of the enjoyment which goes with this type of Joint Working

# And the future?

## WEAHSN evaluating the impact of QIST



*"It was unobtrusive and useful"*

*"I was skeptical at the start but enjoyed the project and found QIST very supportive and helpful"*

*"Keep the good work up"*

*"QIST support was invaluable"*

There is a need for leadership and overall management of the project to achieve the programme theory. Within this project the leadership and management of the overall project and its completion was largely contributed to the role taken by the AHSN QI team, and the provision of management resources to support

*University of the West of England, Realist Evaluation of DWAC Phase 2*



# Future WEAHSN Collaborations



Joint Working Model good example of how collaboration can work

Working with Pfizer around STP's Emergent projects – Escape Pain, Heart Failure, Diabetes – industry involvement

Enterprise and Translation team collaborating with social enterprise groups and industry partners



